Nuwellis Q1 net sales $2.4M (+26% YoY); gross margin 70.1%; net loss $4.3M

Nuwellis, Inc.

Net sales $2.4M, up 26% from $1.9M YoY; gross margin 70.1% (improved 14% YoY).
Net loss $4.3M; operating expenses $6.0M (up from $4.1M) due to sales headcount.
Cash $2.2M, no debt as of March 31, 2026.
Acquired Rendiatech (kidney-function monitoring); appointed Carisa Schultz as CFO.
Appointed Martin J. Emerson and David A. McDonald to Board; new patents and TX territory.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001140361-26-020805

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.